For example, BRCA1 methylation has been revealed to predict significantly higher response rates to cisplatin treatment in breast and ovarian cancer patients [17], which is also traditionally used as the first-line agent in bladder cancer disease management [21]. The gene discussed is BRCA1; the disease is urinary bladder carcinoma.